Clinical Trial of Cinobufacini Combined With Transarterial Chemoembolization (TACE) on Primary Liver Cancer
Status:
Unknown status
Trial end date:
2020-09-01
Target enrollment:
Participant gender:
Summary
The clinical trail of Cinobufacini combined with TACE on primary liver cancer.The trail is
randomized controled.Patients are diagnosed primary liver cancer based on pathology or cell
biology.They are randomized into 2 groups:both groups receive TACE.The treatment group
receives Cinobufacini injection 20ml via hepatic artery during Transarterial
Chemoembolization(TACE) operation , Cinobufacini injection 20ml+5% Glucose injection 500ml
from the second day of TACE until 7th day, and Cinobufacini tablet 3 tablets Tid for 2
months..The control group only receives TACE.Mainly to study Cinobufacini leads to the
influence of the immunologic function after TACE.Immunological examination and Blood
biochemistry evaluation include the number ratio、activity and function of immune cell,the
immune cell marker(CD3、CD4、CD8,etc),tumor marker(CEA、AFP),etc.Clinical evaluation includes
image data(CT/MRI),drug toxicities,quality of life(QOL),etc.
Phase:
Phase 4
Details
Lead Sponsor:
The First Affiliated Hospital of Dalian Medical University